Next-Gen Immuno-Oncology Congress | June, 21-22

To ensure maximum safety, MarketsandMarkets has initiated a mandatory COVID-19 vaccination policy for all in-person attendees across all our physical events. Attendees will be asked to provide proof of vaccination. Additional details on the vaccine policy will be provided upon registration.

Attendees that cannot participate due to this policy, or because of any travel restrictions, are encouraged to participate in the event by registering virtually and attending the event which will be live streamed on our very well appreciated virtual event platform!

These policies may shift as the virus subsides, but we firmly feel this is the right time for MarketsandMarkets to reopen our much awaited physical events safely! We stay committed in our fight against COVID, a variety of new protocols and elevated practices are in place at the venue along with maintaining high standards of cleanliness. We are strictly adhering to the safety guidelines outlined by the Government. We also encourage our participants to review all federal, state, and local permitted traveler guidance before travel and making a reservation.

The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors

The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors.

Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

With more than 35+ speakers at the congress, they will focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in celluar and viral therapies, vaccines development and personalized immunotherapy.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

Register for our 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020, write an email to [email protected]